These data suggest that GLP-1 RAs or dual GIP/GLP-1 receptor agonists may offer metabolic improvement in some patients with lipodystrophy, including scenarios where daily injections are not tolerated or in geographical regions where metreleptin is not available. This evidence concerns the gene GLP1R and lipodystrophy.